Melanie Maierthaler


+49 6221 56 8403


Im Neuenheimer Feld 440




Colorectal cancer (CRC) is the third most common type of cancer, more than 65,000 patients are diagnosed with colorectal cancer in Germany each year, the lifetime risk exceeds 5 % among both men and women.

Using the 450K Methylation Assay for genome-wide investigation, we aim to reveal DNA methylation signatures as potential prognostic and/ or predictive biomarkers for CRC. The results will most likely contribute to an improved, more individual treatment of CRC in order to avoid under- or overtreatment of patients. Furthermore the study results can help to understand the role of underlying epigenetic mechanisms in CRC with regards to treatment response and long term survival of patients.

to top
powered by webEdition CMS